Additionally, most physicians in the community setting want to initiate treatment quickly but do not have access to on-site molecular testing at their practice. As a result, physicians may delay their decision to commence treatment with specific targeted therapies or treat before the existence of actionable mutations is known. The goal of this study was to assess the utility of blood-based cell-free (cf) DNA Laboratory Developed Tests (LDTs) in the community setting. The tests utilize Droplet Digital™ PCR (ddPCR) technology to detect the EGFR sensitizing mutations L858R and exon 19 deletion (ΔE746-A750), the EGFR resistance mutation (T790M), the KRAS mutations G12C, G12V, and G12D, and the BRAF V600E mutation. Patient samples for testing were collected and shipped at ambient temperature using a Biodesix ® whole blood sample collection kit and processed at the Biodesix Laboratory. Metrics were reviewed from the real-time measurement of established molecular diagnostic markers in the plasma of patients with NSCLC. For this study, we analyzed results from greater than 6,000 patient cases (~44,000 individual variants). Of the sites that self-identify, greater than 80% of test orders were received from physician practices are community-based. Test mutation status results were reported within 72 hours of a sample receipt (96%). The percentage of tests requested that were positive for each variant category were 7.5% for EGFR sensitizing (including L858R and del19), 5.8% for EGFR resistance, 9.8% for KRAS (including G12C/D/V), and 1% for BRAF. Notably, we generated test results successfully for 98% of tests submitted. We have developed rapid, highly robust, and sensitive blood-based assays to expedite time to treatment and expand the laboratory testing options for patients with NSCLC.
Time to treatment can have significant impact on progression of cancer and treatment decisions rely heavily upon genomic and proteomic testing. However, multiple factors can delay the availability of molecular diagnostic test results including the use of tissue-based testing. Almost one third of patients with non-small cell lung cancer (NSCLC) are either not candidates for tissue biopsies or have insufficient tissue samples from their initial biopsy. Additionally, most physicians in the community setting want to initiate treatment quickly but do not have access to on-site molecular testing at their practice. As a result, physicians may delay their decision to commence treatment with specific targeted therapies or treat before the existence of actionable mutations is known. The goal of this study was to assess the utility of blood-based cell-free (cf) DNA Laboratory Developed Tests (LDTs) in the community setting. The tests utilize Droplet Digital™ PCR (ddPCR) technology to detect the EGFR sensitizing mutations L858R and exon 19 deletion (ΔE746-A750), the EGFR resistance mutation (T790M), the KRAS mutations G12C, G12V, and G12D, and the BRAF V600E mutation. Patient samples for testing were collected and shipped at ambient temperature using a Biodesix ® whole blood sample collection kit and processed at the Biodesix Laboratory. Metrics were reviewed from the real-time measurement of established molecular diagnostic markers in the plasma of patients with NSCLC. For this study, we analyzed results from greater than 6,000 patient cases (~44,000 individual variants). Of the sites that self-identify, greater than 80% of test orders were received from physician practices are community-based. Test mutation status results were reported within 72 hours of a sample receipt (96%). The percentage of tests requested that were positive for each variant category were 7.5% for EGFR sensitizing (including L858R and del19), 5.8% for EGFR resistance, 9.8% for KRAS (including G12C/D/V), and 1% for BRAF. Notably, we generated test results successfully for 98% of tests submitted. We have developed rapid, highly robust, and sensitive blood-based assays to expedite time to treatment and expand the laboratory testing options for patients with NSCLC. • 
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We would like to thank our patients, as well as all members of team Biodesix and team Bio-Rad. Figure 2 . Overview of GeneStrat ® Sample Processing for cfDNA in the Biodesix Laboratory. Patient sample testing is initiated when whole blood drawn into blood collection tubes arrives at the Biodesix Laboratory. Patient samples for testing are accessioned into the Laboratory Information Management System (LIMS). Following nucleic acid extraction, samples are processed using the Bio-Rad QX200 TM Droplet Digital PCR (ddPCR) system. Numbers of mutant and wild-type copies are assessed using QuantaSoft Software, and Test Result Reports (TRRs) are generated from the secure LIMS. 
